搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
BioSpace
1 天
Aligos Claims Mid-Stage Win in MASH but Investors Are Skeptical
An unusual placebo effect in Aligos Therapeutics’ Phase IIa trial is driving shareholder skepticism for its metabolic ...
BioSpace
1 天
Novo’s Next-Gen CB1 Drug Leads to Weight Loss in Phase II, but Neuropsychiatric Events ...
Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...
BioSpace
1 天
ADCs, Bispecifics and Radiopharma Take Center Stage at ESMO24
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...
BioSpace
1 天
Sanofi’s Tolebrutinib Delays MS Progression in Phase III Study Following Earlier Flops
The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...
BioSpace
2 天
4DMT’S Gene Therapy for AMD Clears Phase II, Heads to Late-Stage Studies
D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for ...
BioSpace
2 天
After Fed Rate Cut, Biotech Stocks Face ‘Anticlimactic’ Reality
The drop in interest rate is slightly bigger than anticipated and good news for the biotech industry, but little will change ...
BioSpace
2 天
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
BioSpace
2 天
Schizophrenia Space Anticipates First-in-Class FDA Approval for BMS’ KarXT
With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...
BioSpace
3 天
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
BioSpace
5 天
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...
BioSpace
4 天
Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies
Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...
BioSpace
3 天
Sickle Cell Gene Therapies Reach Patients, Moderna Cuts, Obesity Pill Race and ESMO 2024
Infusions of Vertex and CRISPR Therapeutics’ Casgevy and bluebird bio’s Lyfgenia have begun; Moderna targets 10 approvals ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈